CN114787191A - 抗pd-l1抗体制剂 - Google Patents

抗pd-l1抗体制剂 Download PDF

Info

Publication number
CN114787191A
CN114787191A CN202080085014.1A CN202080085014A CN114787191A CN 114787191 A CN114787191 A CN 114787191A CN 202080085014 A CN202080085014 A CN 202080085014A CN 114787191 A CN114787191 A CN 114787191A
Authority
CN
China
Prior art keywords
formulation
liquid pharmaceutical
antibody
pharmaceutical formulation
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080085014.1A
Other languages
English (en)
Chinese (zh)
Inventor
A·惠
J·朱-希莫尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN114787191A publication Critical patent/CN114787191A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080085014.1A 2019-12-09 2020-12-07 抗pd-l1抗体制剂 Pending CN114787191A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945730P 2019-12-09 2019-12-09
US62/945,730 2019-12-09
PCT/US2020/063620 WO2021118930A2 (en) 2019-12-09 2020-12-07 Anti-pd-l1 antibody formulations

Publications (1)

Publication Number Publication Date
CN114787191A true CN114787191A (zh) 2022-07-22

Family

ID=74206149

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080085014.1A Pending CN114787191A (zh) 2019-12-09 2020-12-07 抗pd-l1抗体制剂

Country Status (15)

Country Link
US (1) US20230039268A1 (cg-RX-API-DMAC7.html)
EP (1) EP4073120A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023504748A (cg-RX-API-DMAC7.html)
KR (1) KR20220113414A (cg-RX-API-DMAC7.html)
CN (1) CN114787191A (cg-RX-API-DMAC7.html)
AU (1) AU2020399619A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011228A2 (cg-RX-API-DMAC7.html)
CA (1) CA3158987A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022001486A1 (cg-RX-API-DMAC7.html)
CR (1) CR20220322A (cg-RX-API-DMAC7.html)
IL (1) IL293580A (cg-RX-API-DMAC7.html)
MX (1) MX2022006784A (cg-RX-API-DMAC7.html)
PE (1) PE20221281A1 (cg-RX-API-DMAC7.html)
TW (1) TWI886185B (cg-RX-API-DMAC7.html)
WO (1) WO2021118930A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026158433A1 (zh) * 2025-01-24 2026-07-30 江苏恒瑞医药股份有限公司 一种包含抗pd-l1抗体的药物组合物及其医药用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
MX2024007749A (es) 2021-12-22 2024-07-01 Genentech Inc Formulaciones clinicas de anticuerpos anti-tigit.
WO2024126750A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Methods for treating cancer
JP2026508415A (ja) * 2023-03-08 2026-03-10 イムノバント サイエンシズ ゲーエムベーハー ポリソルベート賦形剤を含む高濃度タンパク質製剤およびその製造方法
WO2025085404A1 (en) 2023-10-16 2025-04-24 Genentech, Inc. Diagnostic and therapeutic methods for treating lung cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029892A2 (en) * 2009-09-11 2011-03-17 F. Hoffmann-La Roche Ag Highly concentrated pharmaceutical formulations
EP2687202A1 (en) * 2009-07-31 2014-01-22 F. Hoffmann-La Roche AG Subcutaneous anti-her2 antibody formulation
CN105793288A (zh) * 2013-09-27 2016-07-20 豪夫迈·罗氏有限公司 抗pdl1抗体配制剂
WO2018136412A2 (en) * 2017-01-17 2018-07-26 Genentech, Inc. Subcutaneous her2 antibody formulations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2687202A1 (en) * 2009-07-31 2014-01-22 F. Hoffmann-La Roche AG Subcutaneous anti-her2 antibody formulation
WO2011029892A2 (en) * 2009-09-11 2011-03-17 F. Hoffmann-La Roche Ag Highly concentrated pharmaceutical formulations
CN105793288A (zh) * 2013-09-27 2016-07-20 豪夫迈·罗氏有限公司 抗pdl1抗体配制剂
WO2018136412A2 (en) * 2017-01-17 2018-07-26 Genentech, Inc. Subcutaneous her2 antibody formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. JACKISCH ET AL.: "Subcutaneous Administration of Monoclonal Antibodies in Oncology", 《GEBURTSH FRAUENHEILK》, vol. 74, no. 4, 30 April 2014 (2014-04-30), pages 343 - 349, XP055344155, DOI: 10.1055/s-0034-1368173 *
XANTHE M. LAM ET AL.: "Antioxidants for Prevention of Methionine Oxidation in Recombinant Monoclonal Antibody HER2", 《JOURNAL OF PHARMACEUTICAL SCIENCES》, vol. 86, no. 11, 30 November 1997 (1997-11-30), pages 1250 - 1255, XP008038003, DOI: 10.1021/js970143s *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026158433A1 (zh) * 2025-01-24 2026-07-30 江苏恒瑞医药股份有限公司 一种包含抗pd-l1抗体的药物组合物及其医药用途

Also Published As

Publication number Publication date
PE20221281A1 (es) 2022-09-05
CL2023001140A1 (es) 2023-10-06
CL2022001486A1 (es) 2023-01-20
JP2023504748A (ja) 2023-02-06
IL293580A (en) 2022-08-01
JP2026009902A (ja) 2026-01-21
CR20220322A (es) 2022-07-28
AU2020399619A1 (en) 2022-06-09
KR20220113414A (ko) 2022-08-12
TWI886185B (zh) 2025-06-11
BR112022011228A2 (pt) 2022-10-11
US20230039268A1 (en) 2023-02-09
MX2022006784A (es) 2022-07-11
CA3158987A1 (en) 2021-06-17
WO2021118930A2 (en) 2021-06-17
EP4073120A2 (en) 2022-10-19
TW202128223A (zh) 2021-08-01
WO2021118930A3 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
JP6934919B2 (ja) 高度に濃縮された薬学的製剤
JP7483376B2 (ja) プログラム死受容体1(pd-1)抗体の安定製剤およびその使用方法
TWI886185B (zh) 抗pd-l1抗體調配物
ES2413090T5 (es) Formulación subcutánea de anticuerpo anti-HER2
CA3040423A1 (en) Anti-edb antibodies and antibody-drug conjugates
RU2855065C1 (ru) Составы на основе антитела к pd-l1
HK40068833A (en) Anti-pd-l1 antibody formulations
HK1174553B (en) Highly concentrated pharmaceutical formulations comprising anti - cd20 antibody
EA041673B1 (ru) Высококонцентрированные фармацевтические композиции, содержащие антитело к cd20, их применение и способ лечения с помощью таких композиций
HK1172236B (en) Subcutaneous anti-her2 antibody formulation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068833

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination